Rigel Pharmaceuticals, Inc. (RIGL)

From the record

Rigel Pharmaceuticals, Inc.'s filings since 2017 show 2 warning events: a notice about its exchange listing (8-K item 3.01, 2 times, the latest 2023-11-30) (its current reports).

From the record

Rigel Pharmaceuticals, Inc.'s 10 filed years say what it did: revenue went from $20 million in fiscal 2016 to $294 million in fiscal 2025, up 34.5% a year; it rose in 6 of 9 years; the deepest fall was 78% from fiscal 2016 to fiscal 2017; net income was positive in 2 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Rigel Pharmaceuticals, Inc.'s diluted share count grew about 3.4% a year, and dividends and buybacks returned about 0% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 3 sales (2 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-09-30 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Rigel Pharmaceuticals, Inc. earned about 94 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 53 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 24 cents per dollar of assets, and net share issuance: its share count grew 6.5% over the year (the filed statements).

From the record

Rigel Pharmaceuticals, Inc.'s standing among 315 graded names in its industry family: revenue of $294 million in fiscal 2025 ranks in the top 24% by size; a net margin of 124.7% ranks in the top 2%; revenue growth of 34.8% a year over the last 3 filed years ranks in the top 28% (its annual reports).

From the record

Rigel Pharmaceuticals, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Rodriguez, Raul R (CEO, President, as filed), filing under that title since 2015-01-28, 11.8 years (top 12% of its family); the 12 officers and directors filing in the last fifteen months have been on the record a median of 5.9 years (top 45%); 7 officer or director changes were reported on Form 8-K since 2023-11-13, against the 12 people in charge now (bottom 35%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Rigel Pharmaceuticals, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $41 million against debt of $53 million leaves -2.3% of its assets as net cash, bottom 12% of its family; cash from operations less capital spending is 25.7% of revenue (top 9%); a gross margin of 93.3% (top 9%); research spending of 11.3% of revenue (bottom 16%) (its annual report).

From the record

Rigel Pharmaceuticals, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 34.8% a year over the last three filed years against 34.5% over all 10, speeding up (top 30% of its family); the newest year grew 64.2% (top 21%); research spending grew 16.5% a year (top 27%); capital spending grew -32.4% a year (bottom 35%) (its annual reports). Rigel Pharmaceuticals, Inc. reported 5 product lines in fiscal 2025: Product at $232 million (79%), Release of Share Cost Liability at $40 million (14%), Royalty Delivery of Drug Supplies and Others at $19 million (7%), and 2 more; 1 of 2 grew against the year before (its annual report).

From the record

Rigel Pharmaceuticals, Inc.'s newest year against its own record: revenue of $294 million in fiscal 2025 came in 34.4% above the $219 million its prior three years' pace pointed to (top 22% of its family); net income of $367 million against a prior three-year average of $22 million (top 2%); a net margin of more than its whole revenue against -20.1% before (top 30%) (its annual reports).